Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging trial of tildacerfont in adults with classic congenital adrenal hyperplasia
NL-OMON52374Phase 2Recruiting
- Sponsor
- Spruce Biosciences, Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tildacerfont in classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (21-OHD) (4 arms), sponsored by Spruce Biosciences, Inc. Primary endpoint: Primary objective detail. Started May 2021; status: recruiting.
02
Drugs
tildacerfont
03
Conditions
classic congenital adrenal hyperplasia21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on NL-OMON52374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52374.